Breaking News Instant updates and real-time market news.

SQ

Square

$14.31

0.415 (2.99%)

, AERI

Aerie Pharmaceuticals

$45.00

-1.95 (-4.15%)

10:41
02/17/17
02/17
10:41
02/17/17
10:41

On The Fly: Top five analyst initiations

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Square (SQ) initiated with a Buy at Citi by analyst Peter Christiansen, who said the company has the capability of "redefining" brick-and-mortar payments and commerce enablement. 2. Aerie Pharmaceuticals (AERI) initiated by Roth Capital analyst Sa'ar Yaniv with a Buy rating and $69 price target as he expects Rhopressa and Roclatan approval in 2018 and 2019. 3. Aegis analyst Chris Kapsch initiated Albemarle (ALB) with a Buy and a $108 price target, calling it a "must-own" stock over at least the next couple years. 4. Arch Coal (ARCH) initiated with a Buy at Jefferies by analyst Christopher LaFemina, citing the company's portfolio of "low-cost" U.S. coal assets and a "clean" balance sheet. 5. Piper Jaffray analyst Erinn Murphy assumed coverage of Nordstrom (JWN) with a Neutral rating and $41 price target, saying she believes price transparency may continue to hinder the company's results. Murphy also assumed coverage of J.C. Penney (JCP) with a Neutral rating and $8 price target, noting worries about the underlying secular pressure Amazon.com (AMZN) is putting on the industry, and assumed coverage of Kohl's (KSS) with a Neutral rating and $40 price target, as she believes earnings growth will be tough amid the current environment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

SQ

Square

$14.31

0.415 (2.99%)

AERI

Aerie Pharmaceuticals

$45.00

-1.95 (-4.15%)

JWN

Nordstrom

$45.45

1.27 (2.87%)

JCP

J.C. Penney

$6.96

-0.075 (-1.07%)

KSS

Kohl's

$41.62

0.085 (0.20%)

AMZN

Amazon.com

$844.14

1.44 (0.17%)

ARCH

Arch Coal

$74.01

1.9 (2.63%)

ALB

Albemarle

$92.25

-0.16 (-0.17%)

  • 17

    Feb

  • 17

    Feb

  • 21

    Feb

  • 22

    Feb

  • 23

    Feb

  • 23

    Feb

  • 24

    Feb

  • 28

    Feb

  • 28

    Feb

  • 16

    Mar

  • 19

    Mar

  • 21

    Mar

  • 21

    Mar

  • 28

    Mar

SQ Square
$14.31

0.415 (2.99%)

02/17/17
SBSH
02/17/17
INITIATION
Target $20
SBSH
Buy
Square initiated with a Buy at Citi
Citi analyst Peter Christiansen started Square with a Buy rating and $20 price target, which represents 44% upside to the shares. The company has the capability of "redefining brick-n-mortar payments and commerce enablement within the vast small and micro-merchant category," the analyst contends. He notes that companies beginning to scale into profitability have often been strong stock performers.
12/28/16
SPHN
12/28/16
NO CHANGE
Target $19
SPHN
Overweight
Square price target raised to $19 from $15 at Stephens
Stephens analyst Brett Huff raised his price target on Square to $19 from $15, citing economic acceleration, confidence in its model and better visibility on its margin opportunity. The analyst keeps an Overweight rating on Square shares.
12/20/16
12/20/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Square (SQ) initiated with a Buy at Nomura and with a Buy at Guggenheim. 2. Salesforce (CRM) initiated with a Buy at Drexel Hamilton. 3. Regeneron (REGN) initiated at BMO Capital. 4. Zoetis (ZTS) initiated with a Buy at Deutsche Bank. 5. trivago (TRVG) initiated with a Neutral at Susquehanna. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/20/16
GUGG
12/20/16
INITIATION
Target $16
GUGG
Buy
Square initiated with a Buy at Guggenheim
Guggenheim analyst Jeff Cantwell initiated Square with a Buy and a $16 price target due to strong secular tailwinds in the "electronification" of money.
AERI Aerie Pharmaceuticals
$45.00

-1.95 (-4.15%)

11/03/16
RBCM
11/03/16
NO CHANGE
Target $54
RBCM
Outperform
Correction: RBC says Aerie Pharmaceuticals should be bought at current levels
RBC Capital analyst Adnan Butt says that Aerie Pharmaceuticals (AERI) is facing lower risk and has a greater chance of being acquired than at any time in its history, since its Rhopressa drug looks poised to be approved, while its preparing to release a second set of Phase III data for its Roclatan drug. The analyst says that Roclatan could be best in class. He keeps a $54 price target and Outperform rating on the name and recommends buying the shares. This note corrects an earlier one that mistakenly referenced AerCap (AER) in its title.
12/20/16
ADAM
12/20/16
INITIATION
Target $50
ADAM
Buy
Aerie Pharmaceuticals assumed with a Buy at Canaccord
Baird analyst Dewey Steadman assumed Aerie Pharmaceuticals with a Buy rating and $50 price target to reflect the significant market opportunity for its Rhopressa monotherapy and Roclatan combination therapy.
11/07/16
RBCM
11/07/16
NO CHANGE
RBCM
Several biotech names de-risked, should be bought, says RBC Capital
RBC Capital analyst Adnan Butt names Aerie Pharmaceuticals (AERI), The Medicines Co. (MDCO), Seattle Genetics (SGEN), and TESARO (TSRO) as biotech companies that face little risk and whose stock should be bought at current levels.The Phase 3 data on Aerie's Rhopressa indicates that the drug should be approved for glaucoma, while The Medicines Co's "Carbavance for gram negative infections looks good and PCSK9si for LDL-C lowering is differentiated," the analyst thinks. The commercial opportunity of Seattle Genetics' Adcetris could increase, while the company has multiple anti-cancer drugs beginning Phase 3 trials, and TESARO's Niraparib appears likely to be approved, and its label could be expanded, Butt believes.
02/17/17
ROTH
02/17/17
INITIATION
Target $69
ROTH
Buy
Aerie Pharmaceuticals initiated with a Buy at Roth Capital
Roth Capital analyst Sa'ar Yaniv started Aerie Pharmaceuticals with a Buy rating and $69 price target as he expects Rhopressa and Roclatan approval in 2018 and 2019.
JWN Nordstrom
$45.45

1.27 (2.87%)

02/13/17
COWN
02/13/17
NO CHANGE
Target $50
COWN
Outperform
Nordstrom price target lowered to $50 from $64 at Cowen
Cowen analyst Oliver Chen lowered his price target to $50 from $64 on Nordstrom ahead of Q4 results. The analyst cited signs of apparel weakness, competitor promos, and lackluster accessories/handbag trends. Chen maintained his Outperform rating on Nordstrom shares.
02/16/17
MAXM
02/16/17
NO CHANGE
Target $61
MAXM
Buy
Nordstrom shares oversold ahead of earnings, says Maxim
Maxim analyst Tom Forte said he is "cautiously optimistic" on Nordstrom's Q4 sales believes the shares are oversold at current levels, even factoring in the challenging retail environment. He reiterates a Buy rating and $61 price target on Nordstrom shares ahead of the company's quarterly report, due on February 23.
02/10/17
SUSQ
02/10/17
INITIATION
Target $47
SUSQ
Neutral
Nordstrom initiated with a Neutral at Susquehanna
Target $47.
02/17/17
PIPR
02/17/17
INITIATION
Target $41
PIPR
Neutral
Nordstrom assumed with a Neutral at Piper Jaffray
Piper Jaffray analyst Erinn Murphy assumed coverage of Nordstrom with a Neutral rating and $41 price target. The analyst believes price transparency may continue to hinder the company's results.
JCP J.C. Penney
$6.96

-0.075 (-1.07%)

02/13/17
02/13/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. J.C. Penney (JCP) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Kimberly Greenberger saying valuation appears more balanced following a 14% decline year-to-date and potential catalysts ahead. 2. Regeneron (REGN) upgraded to Overweight from Neutral at Piper Jaffray with analyst Edward Tenthoff saying that while Eylea growth is slowing, new approvals are coming. The analyst expects Dupixent approval in atopic dermatitis by the March 29 FDA action date and Phase III Liberty Asthma Quest data and potential supplemental Biologics License Application by year-end. 3. Petrobras (PBR) upgraded to Overweight from Neutral at JPMorgan with analyst Rodolfo Angele saying the shares are back to September 2016 levels despite "many positive" developments since then. 4. Nucor (NUE) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Evan Kurtz saying Nucor has more favorable risk/reward than AK Steel (AKS), which was downgraded to Equal Weight, given its low cost profile, margin stability, attractive end market mix, and potential benefits from favorable rulings on ongoing rebar and plate trade cases. 5. Allscripts (MDRX) upgraded to Buy from Neutral at Dougherty with analyst Gene Mannheimer citing a strong 2017 outlook partly due to Sunrise expansion, checks that indicate traction in the Allscripts open platform, and opportunities for growth from the NetSmart joint venture. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/13/17
02/13/17
UPGRADE

Equal Weight
J.C. Penney upgraded to Equal Weight on valuation at Morgan Stanley
As previously reported, Morgan Stanley upgraded J.C. Penney to Equal Weight from Underweight. Analyst Kimberly Greenberger said valuation appears more balanced following a 14% decline year-to-date and potential catalysts ahead. The analyst has a new $7 price target, versus $8 previously, and a $12 bull case and $2 bear case values.
02/17/17
PIPR
02/17/17
INITIATION
Target $8
PIPR
Neutral
J.C. Penney assumed with a Neutral at Piper Jaffray
Piper Jaffray analyst Erinn Murphy assumed coverage of J.C. Penney (JCP) with a Neutral rating and $8 price target. The analyst worries about the underlying secular pressure Amazon.com (AMZN) is putting on the industry.
02/13/17
MSCO
02/13/17
UPGRADE
MSCO
Equal Weight
J.C. Penney upgraded to Equal Weight from Underweight at Morgan Stanley
KSS Kohl's
$41.62

0.085 (0.20%)

02/10/17
SUSQ
02/10/17
INITIATION
Target $41
SUSQ
Neutral
Kohl's initiated with a Neutral at Susquehanna
Target $41.
02/17/17
PIPR
02/17/17
INITIATION
Target $40
PIPR
Neutral
Kohl's assumed with a Neutral at Piper Jaffray
Piper Jaffray analyst Erinn Murphy assumed coverage of Kohl's with a Neutral rating and $40 price target. The analyst believes earnings growth will be tough amid the current environment.
01/18/17
01/18/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Disney (DIS) downgraded to Underperform from Market Perform at BMO Capital with analyst Daniel Salmon arguing that the recent positive upturn in investor sentiment and stock performance has come too early, leaving the risk/reward balance skewed to the downside. As reasons for his caution, Salmon cites expectations for more negative data points for ESPN, consensus Studio estimates that he believes may be too high and questions returning around replacing highly regarded CEO Bob Iger. The analyst lowered his price target on Disney shares to $88 from $90. 2. J.C. Penney (JCP) and Kohl's (KSS) were downgraded to Underperform from Neutral at Credit Suisse. 3. Wells Fargo (WFC) downgraded to Hold from Buy at Argus with analyst Stephen Biggar citing valuation and his belief that the company will face "additional revenue headwinds" as it seeks to "repair its reputation." 4. Equifax (EFX) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Toni Kaplan saying she expects higher rates to pressure Equifax's rate-sensitive revenue streams and lowered its price target to $137 from $145. 5. Tiffany (TIF) downgraded to Neutral from Overweight at Atlantic Equities. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/18/17
FBCO
01/18/17
DOWNGRADE
Target $39
FBCO
Underperform
Kohl's downgraded to Underperform at Credit Suisse
As previously reported, Credit Suisse analyst Christian Buss downgraded Kohl's (KSS) to Underperform from Neutral, citing its exposure to less valuable malls and its lack of presence in what he deems to be the most valuable malls. He also cites Kohl's lagging speed to market compared to others in the space. Buss also downgraded J.C. Penney (JCP) to Underperform this morning, citing similar concerns. He lowered his price target on Kohl's shares to $39 from $45.
AMZN Amazon.com
$844.14

1.44 (0.17%)

02/15/17
OPCO
02/15/17
NO CHANGE
Target $970
OPCO
Outperform
Amazon.com price target raised to $970 from $900 at Oppenheimer
Oppenheimer analyst Jason Helfstein raised his price target for Amazon.com to $970 from $900 after cloud returns prove to be much higher than his firm's cloud analyst Tim Horan had originally expected, which should offset near-term concerns on retail investments. The analyst believes CAPX will ramp in the near-term, as Amazon Web Services' utilization in new availability zones increases, and expects lower marginal returns in the longer term given increasing competition/pricing pressure. He reiterates an Outperform rating on the shares.
02/15/17
RBCM
02/15/17
NO CHANGE
RBCM
LogMeln weakness overdone, says RBC Capital
After LogMeIn (LOGM) fell 9% following the launch of Amazon's (AMZN) online meeting offering, Chime, RBC Capital analyst Matthew Hedberg says that Chime "appears to be competitive" with LogMeIn's join.me. However, the analyst says that it will take time for Chime to fully catch up with LogMeIn's features and ease of use. He keeps a $125 price target and an Outperform rating on LogMeIn.
02/14/17
RBCM
02/14/17
NO CHANGE
RBCM
LogMeln selloff on AWS launch of Chime an overreaction, says RBC Capital
RBC Capital Matthew Hedberg said that after speaking with LogMeIn (LOGM) management he views the selloff in the shares following Amazon's (AMZN) introduction of online meeting solution Chime as an overreaction. The introduction of additional productivity applications by AWS should be expected given competitive portfolios, Hedberg said. Today's news, and LogMeIn's reaction, reminds him of WebEx in 2002 when Microsoft (MSFT) introduced a similar, free product, but Microsoft's launch "caused much investor concern but ultimately did not prove disruptive," Hedberg tells investors.
ARCH Arch Coal
$74.01

1.9 (2.63%)

11/10/16
11/10/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. BHP Billiton (BHP) initiated with a Hold at HSBC. 2. Mondelez (MDLZ) reinstated with a Hold at Deutsche Bank. 3. Yum China (YUMC) initiated with an Outperform at Oppenheimer. 4. Arch Coal (ARCH) initiated with a Buy at Seaport Global. 5. Zions Bancorp (ZIOP) coverage assumed with an Outperform at RBC Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/01/16
STFL
12/01/16
NO CHANGE
STFL
Arch Coal price target raised to $91 from $81 at Stifel
Stifel analyst Paul Forward raised his price target on Arch Coal after the company indicated that it would be less sensitive to metallurgical coal price movements next year than it previously expected. Forward believes that the change shows that Arch carried out contracting activity when prices were high. He keeps a Buy rating on the shares.
02/17/17
JEFF
02/17/17
INITIATION
Target $90
JEFF
Buy
Arch Coal initiated with a Buy at Jefferies
Jefferies analyst Christopher LaFemina started Arch Coal with a Buy rating and $90 price target. The company has a portfolio of "low-cost" U.S. coal assets and a "clean" balance sheet, the analyst contends.
12/20/16
MKMP
12/20/16
INITIATION
Target $103
MKMP
Buy
Arch Coal initiated with a Buy at MKM Partners
MKM Partners analyst Daniel Scott initiated Arch Coal with a Buy and a $103 price target and named it his top pick. He believes a prolonged downturn in commodity prices is reversing just as the company exited bankruptcy, setting the stage, for solid performance going forward with the benefit of a clean balance sheet.
ALB Albemarle
$92.25

-0.16 (-0.17%)

01/17/17
BARD
01/17/17
UPGRADE
BARD
Outperform
Albemarle upgraded to Outperform from Neutral at Baird
01/17/17
BARD
01/17/17
UPGRADE
Target $118
BARD
Outperform
Albemarle upgraded to Outperform at Baird
As previously reported, Baird analyst Ben Kallo upgraded Albemarle (ALB) to Outperform from Neutral. The analyst cited his belief in the growth of electric vehicles and storage, especially as Tesla (TSLA) ramps production. He feels the U.S. is in a multi-year growth cycle for lithium and Albemarle shares should benefit until substantial capacity comes on-line. Kallo recommends buying shares at current levels and raised his price target to $118 from $91 on Albemarle.
11/08/16
SBSH
11/08/16
NO CHANGE
SBSH
Albemarle removed from U.S. Focus List at Citi
Citi removed Albemarle from its U.S. Focus List but keeps a Buy rating on the shares.
02/17/17
AGIS
02/17/17
INITIATION
Target $108
AGIS
Buy
Albemarle initiated with a Buy, a 'must own' stock, says Aegis
Aegis analyst Chris Kapsch initiated Albemarle with a Buy and a $108 price target saying it is a "must-own" stock over at least the next couple years. The analyst commented the portfolio transformation may be complete, the earnings story has legs, and shares have higher to go. He expects favorable lithium demand growth and pricing from EDV adoption to drive earnings momentum and said its competitive positioning appears safe for the foreseeable future.

TODAY'S FREE FLY STORIES

23:00
12/13/17
12/13
23:00
12/13/17
23:00
General news
PBoC nudged rates higher »

PBoC nudged rates higher,…

LPSN

LivePerson

$11.05

-0.05 (-0.45%)

20:28
12/13/17
12/13
20:28
12/13/17
20:28
Initiation
LivePerson initiated at B. Riley FBR »

LivePerson initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

HUSKF

Husky Energy

$12.42

-0.1177 (-0.94%)

20:26
12/13/17
12/13
20:26
12/13/17
20:26
Upgrade
Husky Energy rating change at Goldman Sachs »

Husky Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COP

ConocoPhillips

$51.68

-0.28 (-0.54%)

20:25
12/13/17
12/13
20:25
12/13/17
20:25
Upgrade
ConocoPhillips rating change at Goldman Sachs »

ConocoPhillips upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

SAFM

Sanderson Farms

$167.64

0.64 (0.38%)

20:25
12/13/17
12/13
20:25
12/13/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

DB

Deutsche Bank

$19.33

-0.05 (-0.26%)

19:17
12/13/17
12/13
19:17
12/13/17
19:17
Hot Stocks
DBNY, DBTCA raise prime lending rate to 4.5% from 4.25% »

Deutsche Bank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$38.04

-0.06 (-0.16%)

18:47
12/13/17
12/13
18:47
12/13/17
18:47
Hot Stocks
AT&T and Communications Workers of America reach tentative agreement »

AT&T Mobility has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMY

Bristol-Myers

$63.47

0.19 (0.30%)

18:33
12/13/17
12/13
18:33
12/13/17
18:33
Hot Stocks
Bristol-Myers granted exclusive license by Ono Pharma to develop ONO-4578 »

Bristol-Myers and Ono…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 05

    Mar

WFC

Wells Fargo

$59.40

-0.93 (-1.54%)

18:15
12/13/17
12/13
18:15
12/13/17
18:15
Hot Stocks
Breaking Hot Stocks news story on Wells Fargo »

Wells Fargo raises prime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

HBAN

Huntington Bancshares

$14.58

-0.23 (-1.55%)

18:10
12/13/17
12/13
18:10
12/13/17
18:10
Hot Stocks
Huntington Bancshares raises prime rate to 4.5% from 4.25% »

Huntington Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASB

Associated Banc-Corp

$25.10

-0.2 (-0.79%)

18:06
12/13/17
12/13
18:06
12/13/17
18:06
Hot Stocks
Breaking Hot Stocks news story on Associated Banc-Corp »

Associated Banc-Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBS

UBS

$17.90

0.035 (0.20%)

18:05
12/13/17
12/13
18:05
12/13/17
18:05
Periodicals
UBS Wealth Management president Zeltner close to stepping down, Bloomberg says »

UBS Wealth Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$36.64

0.06 (0.16%)

18:03
12/13/17
12/13
18:03
12/13/17
18:03
Hot Stocks
Pfizer announces FDA approves IXIFI, a biosimilar to Remicade »

Pfizer announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jan

CNP

CenterPoint Energy

$28.40

0.02 (0.07%)

18:03
12/13/17
12/13
18:03
12/13/17
18:03
Hot Stocks
CenterPoint Energy raises quarterly dividend 4% to 27.75c per share »

CenterPoint Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDXG

MiMedx

$11.99

-0.26 (-2.12%)

18:03
12/13/17
12/13
18:03
12/13/17
18:03
Recommendations
MiMedx analyst commentary at Piper Jaffray »

Piper reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

CE

Celanese

$108.31

1.34 (1.25%)

18:01
12/13/17
12/13
18:01
12/13/17
18:01
Hot Stocks
Celanese raises acetyl intermediates products prices »

Raises price on Vinyl…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAL

Western Alliance

$57.30

-1.25 (-2.13%)

18:01
12/13/17
12/13
18:01
12/13/17
18:01
Hot Stocks
Western Alliance: Sarver to transition from chairman, CEO to exec chairman in Q1 »

Western Alliance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USB

U.S. Bancorp

$54.60

-0.9 (-1.62%)

18:01
12/13/17
12/13
18:01
12/13/17
18:01
Hot Stocks
U.S. Bancorp raises prime lending rate to 4.50% from 4.25%, effective Dec 14 »

U.S. Bancorp last…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

WBS

Webster Financial

$56.16

-0.73 (-1.28%)

18:00
12/13/17
12/13
18:00
12/13/17
18:00
Hot Stocks
Webster raises prime lending rate to 4.5% from 4.25% »

Webster Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

HSBC

HSBC

$51.44

0.89 (1.76%)

17:56
12/13/17
12/13
17:56
12/13/17
17:56
Hot Stocks
Breaking Hot Stocks news story on HSBC »

HSBC raises prime,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTR

Aqua America

$37.59

0.32 (0.86%)

17:47
12/13/17
12/13
17:47
12/13/17
17:47
Hot Stocks
Aqua America names CEO Christopher Franklin as board chairman »

Aqua America announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

MSFT

Microsoft

$85.35

-0.23 (-0.27%)

17:38
12/13/17
12/13
17:38
12/13/17
17:38
Hot Stocks
Microsoft launches new AI-powered search features for Bing »

Microsoft announced in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

TCF

TCF Financial

$20.24

-0.16 (-0.78%)

17:36
12/13/17
12/13
17:36
12/13/17
17:36
Hot Stocks
Breaking Hot Stocks news story on TCF Financial »

TCF Financial raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMA

Comerica

$84.81

-1.06 (-1.23%)

17:34
12/13/17
12/13
17:34
12/13/17
17:34
Hot Stocks
Comerica Bank raises prime rate to 4.5% from 4.25% »

Comerica Bank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

CMCM

Cheetah Mobile

$11.18

-0.02 (-0.18%)

17:33
12/13/17
12/13
17:33
12/13/17
17:33
Hot Stocks
Breaking Hot Stocks news story on Cheetah Mobile »

Cheetah Mobile up over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.